Skip to main content

Table 2 Baseline pulmonary function parameters and maintenance medications of patients with COPD from the KOCOSS according to the presence of chronic bronchitis and BMI categories

From: Association of body mass index and COPD exacerbation among patients with chronic bronchitis

 

Total (N = 1264)

Non-CB

CB

P

BMI ≥ 25 (n = 230)

BMI < 25 (n = 583)

BMI ≥ 25 (n = 98)

BMI < 25 (n = 353)

Pulmonary function

 Post bronchodilator FVC, L

3.16 ± 0.82

3.14 ± 0.84

3.12 ± 0.82

3.35 ± 0.74

3.20 ± 0.82

0.046

 Post bronchodilator FVC, % pred (N = 1262)

84.1 ± 18.6

82.4 ± 18.9

83.7 ± 17.8

84.3 ± 15.1

85.6 ± 20.4

0.203

 Post bronchodilator FEV1, L

1.61 ± 0.57

1.76 ± 0.56

1.57 ± 0.58

1.82 ± 0.52

1.51 ± 0.53

< 0.0001

 Post bronchodilator FEV1, % pred (N = 1262)

60.8 ± 19.6

66.2 ± 18.8

60.1 ± 20.0

65.4 ± 15.9

57.1 ± 19.4

< 0.0001

  ≥ 80% pred

181 (14.3)

46 (20.0)

83 (14.3)

16 (16.5)

36 (10.2)

< 0.0001

  50% pred ≤ FEV1 < 80% pred

704 (55.8)

146 (63.5)

302 (51.9)

68 (70.1)

188 (53.3)

 

  < 50% pred

377 (29.9)

38 (16.5)

197 (33.8)

13 (13.4)

129 (36.5)

 

 Post bronchodilator FEV1/FVC

0.51 ± 0.13

0.56 ± 0.11

0.51 ± 0.14

0.54 ± 0.11

0.47 ± 0.12

< 0.0001

 Bronchodilator responsea

96 (7.6)

16 (7.0)

32 (5.5)

10 (10.2)

38 (10.8)

0.020

 Diffusing capacity, % pred (N = 970)

75.3 ± 23.8

82.3 ± 21.2

76.1 ± 25.3

79.2 ± 21.9

68.4 ± 21.7

< 0.0001

  < 60% pred

240 (24.7)

20 (11.3)

114 (26.0)

14 (17.3)

92 (33.6)

< 0.0001

 RV/TLC, % (N = 754)

45.0 ± 12.8

43.5 ± 11.5

46.2 ± 13.82

40.4 ± 12.4

45.4 ± 11.8

0.005

 6MWD, m (N = 1003)

374.8 ± 116.5

379.9 ± 110.5

379.8 ± 118.9

388.8 ± 106.9

360.0 ± 118.0

0.071

Baseline medication

 No

116(9.2)

27(11.7)

56(9.6)

7(7.1)

26(7.4)

0.282

 Yes

1148(90.8)

203(88.3)

527(90.4)

91(92.9)

327(92.6)

 

  LAMA (N = 1124)

744 (66.2)

124 (61.7)

334 (64.0)

56 (66.7)

230 (72.6)

0.034

  LABA (N = 1063)

207 (19.5)

31 (16.4)

96 (19.5)

16 (20.5)

64 (21.1)

0.633

  ICS + LABA (N = 1082)

504 (46.6)

77 (38.7)

229 (45.9)

39 (52.0)

159 (51.5)

0.031

  ICS + LABA + LAMA (N = 1058)

395 (37.3)

56 (29.3)

191 (39.1)

20 (28.2)

128 (41.7)

0.012

  PDE-4 inhibitor (N = 1022)

57(5.6)

7(3.8)

23(4.9)

1(1.4)

26(8.7)

0.023

  1. Data are presented as mean ± standard deviation or number (%). P values < 0.05 are presented in bold
  2. BMI, body mass index; CB, chronic bronchitis; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; KOCOSS, Korean COPD Subgroup Study; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; PDE-4 inhibitor, phosphodiesterase-4 inhibitor; RV, residual volume; TLC, total lung capacity; 6MWD, 6-min walk distance
  3. aPositive bronchodilator response was defined as the post-bronchodilator increase in FEV1 or FVC of at least 12% and 200 mL from baseline values at 15 min after inhalation of 400 μg of salbutamol